Skip to main content
Top
Published in: Journal of Assisted Reproduction and Genetics 1/2014

01-01-2014 | Fertility Preservation

Fertility preservation after caesarean delivery in a woman diagnosed with Morbus Hodgkin disease during pregnancy

Authors: Theresa Gundelach, Diane Stuck, Peter Widschwendter, Jürgen M. Weiss, Wolfgang Janni, Katharina Hancke

Published in: Journal of Assisted Reproduction and Genetics | Issue 1/2014

Login to get access

Excerpt

Female fertility preservation before chemotherapy has become a common issue among postpubertal and premenopausal women who desire children. Von Wolff et al. [1] recently published a practical guideline for different fertility preservation techniques, based on data from the FertiPROTEKT network database. The published practical guideline particularly addresses women with breast cancer, Hodgkin disease, or borderline ovarian tumour. The following are the different fertility preservation techniques covered: (1) hormonal stimulation and cryopreservation of unfertilised and fertilised oocytes, (2) cryopreservation of ovarian tissue, and (3) administration of gonadotropin-releasing hormone agonists (GnRHa). There is one or more than 1 option available for cancer patients, depending on cancer type, partnership, and individual desire. …
Literature
1.
go back to reference Von Wolff M et al. Fertility preservation in women: a practical guide to preservation techniques and therapeutic strategies in breast cancer. Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011;284(2):427–35.CrossRef Von Wolff M et al. Fertility preservation in women: a practical guide to preservation techniques and therapeutic strategies in breast cancer. Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011;284(2):427–35.CrossRef
2.
go back to reference Diehl V et al. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003;2003:225–47.CrossRef Diehl V et al. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003;2003:225–47.CrossRef
3.
go back to reference Behringer K et al. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2005;23(30):7555–64.PubMedCrossRef Behringer K et al. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2005;23(30):7555–64.PubMedCrossRef
4.
go back to reference Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000;169(1–2):123–31.PubMedCrossRef Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000;169(1–2):123–31.PubMedCrossRef
5.
go back to reference Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy. Lancet. 2012;379(9815):580–7.PubMedCrossRef Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy. Lancet. 2012;379(9815):580–7.PubMedCrossRef
6.
go back to reference Isachenko V et al. Cryobanking of human ovarian tissue for anti-cancer treatment: comparison of vitrification and conventional freezing. Cryo Lett. 2009;30:449–54. Isachenko V et al. Cryobanking of human ovarian tissue for anti-cancer treatment: comparison of vitrification and conventional freezing. Cryo Lett. 2009;30:449–54.
7.
go back to reference Dolmans MM et al. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril. 2013;99(6):1514–22.PubMedCrossRef Dolmans MM et al. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril. 2013;99(6):1514–22.PubMedCrossRef
8.
go back to reference Kahraman K et al. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. Fertil Steril. 2009;91(6):2437–44.PubMedCrossRef Kahraman K et al. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. Fertil Steril. 2009;91(6):2437–44.PubMedCrossRef
9.
go back to reference Loren AW et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.PubMedCrossRef Loren AW et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.PubMedCrossRef
10.
go back to reference Bedoschi GM et al. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet. 2010;27(8):491–4.PubMedCrossRef Bedoschi GM et al. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet. 2010;27(8):491–4.PubMedCrossRef
Metadata
Title
Fertility preservation after caesarean delivery in a woman diagnosed with Morbus Hodgkin disease during pregnancy
Authors
Theresa Gundelach
Diane Stuck
Peter Widschwendter
Jürgen M. Weiss
Wolfgang Janni
Katharina Hancke
Publication date
01-01-2014
Publisher
Springer US
Published in
Journal of Assisted Reproduction and Genetics / Issue 1/2014
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-013-0126-7

Other articles of this Issue 1/2014

Journal of Assisted Reproduction and Genetics 1/2014 Go to the issue

Editor’s Commentary

Next gen ARTs: what lies ahead?